

Wahiawa General Hospital

August 1, 2018

Nuclear Materials Licensing Branch U.S. Nuclear Regulatory Commission, Region IV 1600 E. Lamar Blvd. Arlington, TX 76011-4511

Subject:	Notification	
	NRC License No.	53-17839-01
	Docket No.	030-13425

Dear License Reviewer:

We have approved the following physicians as Authorized Users:

David Camacho, M.D. for use of byproduct materials listed in 10 CFR 35.100, 35.200, and 35.300. Dr. Camacho is currently authorized for these uses on NRC License #53-27729-01 issued to Kona Community Hospital. A copy of this license is enclosed.

Scott Grosskreutz, M.D. for use of byproduct materials listed in 10 CFR 35.100, 35.200, and 35.300. Dr. Grosskreutz is currently authorized for these uses on NRC License #53-27729-01 issued to Kona Community Hospital. A copy of this license is enclosed.

If you require any additional information please contact our Radiation Safety Consultant, Ronald Frick at 808-373-7009.

Sincerely,

Brian Cunningham Chief Executive Officer

A Normal Release		
NON-PUBLIC		
A.3 Sensitive-Sec		
A.7 Sensitive Intel	rnal	
C Other:		
Reviewer: Amt	Date: 830/18	

PUBLIC

Q, Immediate Release

 $\begin{array}{c} \mathbf{D} \in \mathbf{C} \in \mathbf{I} \\ \mathbf{N} \\ \mathbf{A} \\ \mathbf{H} \\ \mathbf{A} \\ \mathbf{U} \\ \mathbf{C} \\ \mathbf$

DNMS

128 Lehua Street ~ Wahiawa, Hawaii 96786 Ph: (808) 621-8411 NRC FORM 374

6

0

7 3

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 3 PAGES Amendment No. 15

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

	Licen	isee		In accordance wi		4. Expir	ation Date: July 31, 2022
1.	Kona Community Hospital			December 5, 201	EGULS		
2.	79-1019 Haukapila Street Kealakekua, HI 96750		She		per: 53-27729-01 is s entirety to read as		et No.: 030-35998 rence No.:
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical form	8.	Maximum amount that licensee may possess at any one time under this license	9. S	Authorized use
A.	Any byproduct material permitted by 10 CFR 35.100	A.	Any O	A.	As Needed	A.	For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.
B.	Any byproduct material permitted by 10 CFR 35.200	B.	Any	B.	As Needed	B.	For use in imaging and localization studies permitted by 10 CFR 35.200.
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any	ひ なな	3.3 curies total (no single container to exceed 300 millicuries)	C.	For any use permitted by 10 CFR 35.300.
	CONDITIONS						
10.	Licensed material may be of Hawaii).	used	and/or stored only at the li	censee`s facility lo	cated at 79-1019 Haukapila	a Street, ł	Kealakekua, Hawaii (island

 2. Licensed material shall only be used by, or under the supervision of: A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: <u>Authorized User(M.D., D.O., etc.)</u> <u>Material and Use</u> David Camacho, M.D. 35.100; 35.200, 35.300 Scott Grosskreutz, M.D. 35.100; 35.200; 35.300 Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. 	030-35998 R 35.13 and 10 CFR 35.14.	SUPPLEMENTARY SHEET	
SUPPLEMENTARY SHEET Amendment No. 15 I1. The Radiation Safety Officer for this license is Ronald Frick, M.S. I2. Licensed material shall only be used by, or under the supervision of: A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: Authorized User(M.D., D.O., etc.) Material and Use David Camacho, M.D. 35.100; 35.200; 35.300 Scott Grosskreutz, M.D. 35.100; 35.200; 35.300 Kinchel J, Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	R 35.13 and 10 CFR 35.14.	SUPPLEMENTARY SHEET	
 2. Licensed material shall only be used by, or under the supervision of: A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: <u>Authorized User(M.D.,D.O.,etc.)</u> <u>Material and Use</u> David Camacho, M.D. 35.100; 35.200, 35.300 Scott Grosskreutz, M.D. 35.100; 35.200, 35.300 Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. 	R 35.13 and 10 CFR 35.14.		
A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14. B. The following individuals are authorized users for the material and medical uses as indicated: Authorized User(M.D., D.O., etc.) Material and Use David Camacho, M.D. 35.100; 35.200; 35.300 Scott Grosskreutz, M.D. 35.100; 35.200; 35.300 Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Michael J. Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	R 35.13 and 10 CFR 35.14.	The Radiation Safety Officer for this license	1. 1
B.The following individuals are authorized users for the material and medical uses as indicated:Authorized User(M.D., D.O., etc.)Material and UseDavid Camacho, M.D.35.100; 35.200, 35.300Scott Grosskreutz, M.D.35.100; 35.200, 35.300Harvey Nakamura, M.D.35.100; 35.200; 35.300Michael J. Seu, M.D.35.100; 35.200; 35.300Lori L. Wilhelm, M.D.35.100; 35.200; 35.300Robert Saito, M.D.35.100; 35.200; 35.300Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	P	Licensed material shall only be used by, or	2.
B.The following individuals are authorized users for the material and medical uses as indicated:Authorized User(M.D.,D.O.,etc.)Material and UseDavid Camacho, M.D.35.100; 35.200, 35.300Scott Grosskreutz, M.D.35.100; 35.200, 35.300Harvey Nakamura, M.D.35.100; 35.200; 35.300Michael J. Seu, M.D.35.100; 35.200; 35.300Lori L. Wilhelm, M.D.35.100; 35.200; 35.300Robert Saito, M.D.35.100; 35.200; 35.300Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	P	A Individuals permitted to work as author	
Authorized User(M.D.,D.O.,etc.)Material and UseDavid Camacho, M.D.35.100; 35.200; 35.300Scott Grosskreutz, M.D.35.100; 35.200; 35.300Harvey Nakamura, M.D.35.100; 35.200; 35.300Michael J. Seu, M.D.35.100; 35.200; 35.300Lori L. Wilhelm, M.D.35.100; 35.200; 35.300Robert Saito, M.D.35.100; 35.200; 35.300Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	uses as indicated:		3
Authorized User(M.D.,D.O.,etc.)Material and UseDavid Camacho, M.D.35.100; 35.200; 35.300Scott Grosskreutz, M.D.35.100; 35.200; 35.300Harvey Nakamura, M.D.35.100; 35.200; 35.300Michael J. Seu, M.D.35.100; 35.200; 35.300Lori L. Wilhelm, M.D.35.100; 35.200; 35.300Robert Saito, M.D.35.100; 35.200; 35.300Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries		B The following individuals are authorized	
David Camacho, M.D. 35.100; 35.200; 35.300 Scott Grosskreutz, M.D. 35.100; 35.200; 35.300 Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Michael J. Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	- 20 - 20 - 2 - 2 - 2 - 2 - 2 - 2 - 2 -	-	
Scott Grosskreutz, M.D. 35.100; 35.200; 35.300 Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Michael J. Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries			
Harvey Nakamura, M.D. 35.100; 35.200; 35.300 Michael J. Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries			
Michael J. Seu, M.D. 35.100; 35.200; 35.300 Lori L. Wilhelm, M.D. 35.100; 35.200; 35.300 Robert Saito, M.D. 35.100; 35.200; 35.300 Ming Yu Peng, M.D. 35.100; 35.200; 35.300 Eric Wyatt, M.D. 35.100; 35.200; 35.300 Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	\leq		
Lori L. Wilhelm, M.D.35.100; 35.200; 35.300Robert Saito, M.D.35.100; 35.200; 35.300Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	100 S		
Ming Yu Peng, M.D.35.100; 35.200; 35.300Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	De la ca		
Eric Wyatt, M.D.35.100; 35.200; 35.300Brian Shukri, D.O.Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries	6	Robert Saito, M.D.	
Brian Shukri, D.O. Oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries		Ming Yu Peng, M.D.	
N N N N N	2	Eric Wyatt, M.D.	
3. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the	iodide I-131 in quantities less than or equal to 33 millicuries	Brian Shukri, D.O.	
	e possession of licensed material to quantities below the	In addition to the possession limits in Item 8	3.
minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.			

.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMM	SSION PAGE 3 OF 3 PAGES
MATERIALS LICENSE	License Number 53-27729-01	Docket or Reference Number 030-35998
SUPPLEMENTARY SHEET	Amendment No. 15	
representations, and procedures containe those procedures that are required to be s licensee's ability to make changes to the	submitted in accordance with the regulations. Ac radiation protection program as provided for in 1 less the statements, representations, and proce	sted below. This license condition applies only to Iditionally, this license condition does not limit the 0 CFR 35.26. The U.S. Nuclear Regulatory
A. Application dated May 18, 2012 (ML12	150A177)	24
B. Letter dated July 17, 2012 with enclosu	STAT A CULTURE STAT	NMNSS
3	FOR	THE U.S. NUCLEAR REGULATORY COMMISSION
	By:	/RA/

Hill, Carol

5

From:	Ronald Frick <rfrick@gammacorp.com></rfrick@gammacorp.com>
Sent:	Saturday, August 18, 2018 12:01 AM
То:	Hill, Carol
Subject:	[External_Sender] Wahiawa General Hospital
Attachments:	wgh_notif2.pdf

Hi Carol,

Attached is a notification for Wahiawa General Hospital, which adds two Authorized Users. Please contact me if you need additional information.

Thank you, Ron Frick Gamma Corporation



Ma 6 0 9 7 7 3

NRC FORM 532	U.S. NUCLEAR REGULATORY COMMISSION				
ACKNOWLEDGEMENT - RECEIPT OF CORRESPONDENCE					
Name and Address of Applicant and/or Licensee	Date				
	08/30/2018				
Mr. Gary Ropert	License Number(s)				
Radiation Safety Officer	53-17839-01				
Wahiawa General Hospital 128 Lehua Street	Mail Control Number(s)				
Wahiawa, HI 96786	609773				
	Licensing and/or Technical Reviewer or Branch				
	C. Hill				
This is to acknowledge receipt of your: 🖌 Letter and	d/or Application Dated: 08/01/2018				
The initial processing, which included an administrative review, has been performed. ✓ Amendment Termination New License Renewal					
There were no administrative omissions identified of	during our initial review.				
This is to acknowledge receipt of your application for renewal of the material(s) license identified above. Your application is deemed timely filed, and accordingly, the license will not expire until final action has been taken by this office.					
Your application for a new NRC license did not include your taxpayer identification number. Please complete and submit NRC Form 531, Request for Taxpayer Identification Number, located at the following link: http://www.nrc.gov/reading-rm/doc-collections/forms/nrc531.pdf Follow the instructions on the form for submission.					
The following administrative omissions have been	identified:				
Your application has been assigned the above listed MAIL CONTROL NUMBER. When calling to inquire about this action, please refer to this control number. Your application has been forwarded to a technical reviewer. Please note that the technical review, which is normally completed within 180 days for a renewal application (90 days for all other requests), may identify additional omissions or require additional information. If you have any questions concerning the processing of your application, our contact information is listed below:					
Region IV U. S. Nuclear Regulatory Commissio DNMS/NMSB - B 1600 E. Lamar Boulevard Arlington, TX 76011-4511 (817) 200-1103 or (817) 200-1140	on				

V 8/30/18

BETWEEN: [FOR ARPB USE] INFORMATION FROM WBL Accounts Receivable/Payable Program Code: 02120 and Status Code: Pending Amendment **Regional Licensing Branches** Fee Category:7C Exp. Date: 08/31/2025 Fee Comments: CODE 23 Decom Fin Assur Regd: N License Fee Worksheet - License Fee Transmittal A. REGION 1. APPLICATION ATTACHED Applicant/Licensee: Wahiawa General Hospital 08/20/2018 Received Date: 3013425 Docket Number: Mail Control Number: 609773 53-17839-01 License Number:

2. FEE ATTACHED
Amount:

3. COMMENTS

Check No.:

Action Type:

Signed: Date:

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered / /)

1. Fee Category and Amount:

2. Correct Fee Paid. Application may be processed for:

Amendment

Amendment:			
Renewal:		6	
License:			
3. OTHER			
	Signed:		
	Date:		